Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Neoadjuvant Atezolizumab and Adjuvant Atezolizumab + Bevacizumab in Combination With Percutaneous Radiofrequency Ablation of Small HCC: a Multicenter Randomized Phase II Trial

NCT04727307 is registered in ClinicalTrials.gov with University Hospital, Montpellier as lead sponsor.

NCT NCT04727307
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04727307 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Neoadjuvant Atezolizumab and Adjuvant Atezolizumab + Bevacizumab in Combination With Percutaneous Radiofrequency Ablation of Small HCC: a Multicenter Randomized Phase II Trial
Lead sponsor
University Hospital, Montpellier
Phase
Phase 2
Overall status
Active, not recruiting
Start date
February 23, 2021
Completion date
February 28, 2031
Enrollment
202 (estimated)
Sites
19

Conditions

As the registry lists them; a condition with its own page is linked.

hepatocellular carcinoma